Viridian Therapeutics, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Viridian Therapeutics, Inc. has filed its 2023 annual report (10-K) detailing its operations and financial standing for the fiscal year ending December 31, 2023.</b>

AI Summary

Viridian Therapeutics, Inc.\DE (VRDN) filed a Annual Report (10-K) with the SEC on February 27, 2024. Viridian Therapeutics, Inc. filed its 2023 Form 10-K on February 27, 2024. The company was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc. Its principal business address is located at 221 Crescent Street, Building 17, Suite 401, Waltham, MA 02453. The SIC code for Viridian Therapeutics is 8071 (Services-Medical Laboratories). The filing covers the fiscal year ending December 31, 2023.

Why It Matters

For investors and stakeholders tracking Viridian Therapeutics, Inc.\DE, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Viridian Therapeutics' financial performance, operational activities, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's current health and future prospects. Understanding the company's historical name changes (Miragen Therapeutics, Inc., Signal Genetics, Inc.) and its SIC code (8071) helps contextualize its evolution and industry positioning within the medical laboratories sector.

Risk Assessment

Risk Level: low — Viridian Therapeutics, Inc.\DE shows low risk based on this filing. The filing is a standard 10-K annual report, which typically contains routine financial and operational information without immediate, significant new risks or opportunities.

Analyst Insight

Review the full 10-K filing for detailed financial statements, risk factors, and management discussion to understand Viridian Therapeutics' performance and outlook.

Key Numbers

• 2023-12-31 — Fiscal Year End (Viridian Therapeutics, Inc.)
• 2024-02-27 — Filing Date (Form 10-K)
• 001-36483 — SEC File Number (Viridian Therapeutics, Inc.)
• 471187261 — IRS Number (Viridian Therapeutics, Inc.)

Key Players & Entities

• Viridian Therapeutics, Inc. (company) — Filer name
• Miragen Therapeutics, Inc. (company) — Former company name
• Signal Genetics, Inc. (company) — Former company name
• Waltham, MA (location) — Business address city and state
• 2023-12-31 (date) — Fiscal year end
• 2024-02-27 (date) — Filing date
• 8071 (other) — Standard Industrial Classification code

FAQ

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-02-27: Filing Date — Date the 10-K was officially filed with the SEC.

Glossary

10-K

An annual report required by the U.S. Securities and Exchange Commission (SEC), which gives a comprehensive summary of a company's financial performance. (This filing provides the official annual financial and operational overview for Viridian Therapeutics, Inc.)

SIC Code

Standard Industrial Classification code, used to classify businesses by the type of activity in which they are engaged. (Identifies Viridian Therapeutics' industry as Medical Laboratories (8071).)

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value per share VRDN The Nasdaq Sto

Filing Documents

• vrdn-20231231.htm (10-K) — 1862KB
• ex45-viridianxdescriptiono.htm (EX-4.5) — 41KB
• ex102-vrdnxformofindemnity.htm (EX-10.2) — 101KB
• ex106-viridianxexecutiveem.htm (EX-10.6) — 85KB
• ex109-cuillaexecutiveemplo.htm (EX-10.9) — 94KB
• ex1010-viridianxexecutivee.htm (EX-10.10) — 95KB
• ex1011-sharmon_amendmentto.htm (EX-10.11) — 13KB
• ex1012-viridianxexecutivee.htm (EX-10.12) — 94KB
• ex1016-vrdn_xxformxofxstoc.htm (EX-10.16) — 96KB
• ex1017-vrdnxformofrsugrant.htm (EX-10.17) — 45KB
• ex1018-employeestockpurcha.htm (EX-10.18) — 86KB
• ex211subsidiaries.htm (EX-21.1) — 6KB
• ex23_1xfinalconsentx2023.htm (EX-23.1) — 2KB
• fy202310kex311.htm (EX-31.1) — 11KB
• fy202310kex312.htm (EX-31.2) — 12KB
• fy202310kex321.htm (EX-32.1) — 9KB
• ex971-vrdnxclawbackpolicya.htm (EX-97.1) — 27KB
• vrdn-20231231_g1.jpg (GRAPHIC) — 4KB
• vrdn-20231231_g2.jpg (GRAPHIC) — 75KB
• vrdn-20231231_g3.jpg (GRAPHIC) — 125KB
• vrdn-20231231_g4.jpg (GRAPHIC) — 148KB
• vrdn-20231231_g5.jpg (GRAPHIC) — 118KB
• 0001590750-24-000007.txt (&nbsp;) — 10658KB
• vrdn-20231231.xsd (EX-101.SCH) — 53KB
• vrdn-20231231_cal.xml (EX-101.CAL) — 76KB
• vrdn-20231231_def.xml (EX-101.DEF) — 335KB
• vrdn-20231231_lab.xml (EX-101.LAB) — 794KB
• vrdn-20231231_pre.xml (EX-101.PRE) — 514KB
• vrdn-20231231_htm.xml (XML) — 1015KB

BUSINESS

BUSINESS 7 ITEM 1A.

RISK FACTORS

RISK FACTORS 37 ITEM 1B. UNRESOLVED STAFF COMMENTS 70 ITEM 1C. CYBERSECURITY 70 ITEM 2.

PROPERTIES

PROPERTIES 71 ITEM 3.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 71 ITEM 4. MINE SAFETY DISCLOSURES 72 PART II ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 73 ITEM 6. RESERVED 73 ITEM 7.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 73 ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 82 ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 82 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 82 ITEM 9A.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 82 ITEM 9B. OTHER INFORMATION 83 ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTION 83 PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE 84 ITEM 11.

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 84 ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 84 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE 84 ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES 84 PART IV ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES 85 ITEM 16. FORM 10-K SUMMARY 87

SIGNATURES

SIGNATURES 3 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K ("Annual Report") contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements contained in this Annual Report include, but are not limited to, statements about: the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results; the potential utility, efficacy, potency, safety, clinical benefits, half-life, clinical response and convenience of our product candidates; the timing and focus of our ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; supply chain disruptions, enrollment in clinical trials involving our product candidates or other delays in such trials; our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy; the size of the market opportunity for our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; the rate and degree of market acceptance and clinical utility for our product candidates; the success of competing therapies that are or may become available; expectations regarding the initiation of clinical trials and interactions and alignment with regulatory authorities; the timing or likelihood of regulatory filings and approvals,

BUSINESS

ITEM 1. BUSINESS Company Overview We are a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases. We target disease areas where marketed therapies often leave room for improvements in efficacy, safety, and/or dosing convenience. We believe that first-generation medicines rarely represent optimal solutions, especially in rare disease areas, and that there is potential to develop differentiated, best-in-class medicines that could lead to improved patient outcomes, reduced side effects, improved quality of life, expanded market access, and augmented market competition. Our business model is designed to identify and evaluate product opportunities in disease areas where trial data establishes proof-of-concept for a drug target in the clinic, but the competitive evolution of the product life cycle management and number of entrants appears incomplete. We intend to prioritize indications where a fast-follower and a potentially differentiated drug candidate, or overall product profile, could create significant medical benefit for patients. We are engineering medicines to address unmet medical needs for patients and further advance drug innovation. Our goal is to identify and evaluate product concepts leveraging clinically validated molecular targets using established therapeutic modalities. We prioritize product concepts that are aligned with clinical and commercial hypotheses, which we expect will provide an attractive balance of risk and opportunity, thereby representing a compelling allocation of our resources. We focus on advancing therapeutic proteins, including antibodies, that we either in-license or discover internally, incorporating proprietary therapeutic protein and antibody discovery and optimization platforms to advance clinical candidates with unique characteristics. We have built relevant expertise in protein and antibody discovery and engineering, biologics manufacturing, nonclinica

View Full Filing

View this 10-K filing on SEC EDGAR